e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
Advances in the therapy of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma
Audrey Benguigui (Rouen, France), Audrey Benguigui, Florian Guisier, Aude Lamy, Suzanna Bota, Samy Lachkar, Mathieu Salaün, Luc Thiberville
Source:
International Congress 2015 – Advances in the therapy of lung cancer
Session:
Advances in the therapy of lung cancer
Session type:
Oral Presentation
Number:
267
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Audrey Benguigui (Rouen, France), Audrey Benguigui, Florian Guisier, Aude Lamy, Suzanna Bota, Samy Lachkar, Mathieu Salaün, Luc Thiberville. Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma. Eur Respir J 2015; 46: Suppl. 59, 267
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
To code or not to code chronic pulmonary aspergillosis associated malnutrition in PMSI database: that is the problem…
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
Breast metastasis from primary EGFR-mutated lung carcinoma or primary tumor?
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Analysis of clinicopathological characteristics of 982 lung cancer patients and subsequent treatment – Epidemiology study
Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases
Year: 2013
RT-PCR expression of EML4-ALK oncogene in Bulgarian patients with non-small cell lung cancers
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Prognostic value of EGFR mutation in NSCLC in surgical stage
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Prevalence of mutations in Romanian patients with non-squamous lung carcinoma evaluated through next generation sequencing
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Prevalence of molecular changes in resected pulmonary adenocarcinomas
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement: Analysis of two cases and literature review
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Multiple primary malignancies in Japanese patients with non-small cell lung cancer
Source: Annual Congress 2013 –Epidemiology of respiratory disease
Year: 2013
EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Cytology sample from EBUS-TBNA for multi-gene analysis in non-small-cell lung cancer (NSCLC)
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
EGFR frequency and response to chemotherapy in a Brazilian NSCLC population
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Clinical features and prognosis of multiple primary malignancies in patients with lung cancer
Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases
Year: 2013
EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
ALK/EML4 translocation in non-squamous NSCLC and their predictors
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Differences in epidemiological and clinical features in non-small cell lung cancer (NSCLC) in never and ever smokers
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept